China Pharma Holding's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 20.26.
China Pharma Holding's Days Inventory for the
three
months ended in Mar. 2026 was 203.65.
China Pharma Holding's Days Payable for the
three
months ended in Mar. 2026 was 112.79.
Therefore, China Pharma Holding's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 111.12.
China Pharma Holding (AMEX:CPHI) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
China Pharma Holding Cash Conversion Cycle Related Terms
China Pharma Holding Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPHI vs TXMD, RMTI, AYTU: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Cash Conversion Cycle falls into.
China Pharma Holding Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
China Pharma Holding's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (CPHI) has a Cash Conversion Cycle of 111.12 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on China Pharma Holding and its competitors.
Is China Pharma Holding's Cash Conversion Cycle too high?
China Pharma Holding's current Cash Conversion Cycle is 111.12. The Drug Manufacturers industry median Cash Conversion Cycle is 145.87. China Pharma Holding's value of 111.12 is 23.8% below this industry median. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Cash Conversion Cycle compare to TXMD and RMTI?
China Pharma Holding's Cash Conversion Cycle of 111.12 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.87. China Pharma Holding's value of 111.12 is 23.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.87, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Pharma Holding's current Cash Conversion Cycle of 111.12 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current Cash Conversion Cycle is 111.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current Cash Conversion Cycle is 111.12 and 23.8% below the Drug Manufacturers industry median of 145.87. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current Cash Conversion Cycle is 111.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (CPHI) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24.
GuruFocus considers China Pharma Holding to be Significantly Overvalued.
Key valuation signals for CPHI:
Cash Conversion Cycle: 111.12
GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
Industry Position: 23.8% below the Drug Manufacturers median
No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for CPHI
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHI has been successfully added to your 
